Condition
Cutaneous Melanoma, Stage III
Total Trials
7
Recruiting
3
Active
4
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 7 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
Early P 1 (1)
P 2 (3)
Trial Status
Recruiting3
Completed2
Unknown1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT07049276Not ApplicableRecruitingPrimary
The Multicentre Selective Lymphadenectomy Trial - 3
NCT07230613Phase 2RecruitingPrimary
Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
NCT07148245Recruiting
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
NCT03719131Phase 2Active Not RecruitingPrimary
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
NCT04853602UnknownPrimary
IFx-Hu2.0 Expanded Access Program
NCT03655756Early Phase 1CompletedPrimary
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
NCT03541148Phase 2Completed
Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma
Showing all 7 trials